1. Scrip
  2. >>Business

Roche Gears Up For Potential Neuroscience Breakthroughs

Huntington’s Drug Could Get Nod in 2020

 
• By Andrew McConaghie

Neuroscience could be this decade’s big growth story, but clinical and market access challenges differ to oncology.

Roche_HQ
Roche's HQ in Basel, Switzerland

One of the most eye-catching remarks made at last week’s J.P. Morgan conference in San Francisco was a bold prediction by Roche’s pharma division head Bill Anderson.

He told investors: “We think that neuroscience has the potential to be in the '20s what oncology has been in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.